ArticleBMJ open2023

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.

Anouk Donners et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.